合生生物完成数千万元Pre-A轮融资，创始人刘斌为南开大学教授

Group 1 - Tianjin Hesheng Biotechnology Co., Ltd. completed a Pre-A round financing of several tens of millions, led by Bohai Chuangfu Securities Investment Co., Ltd. with participation from Tianjin Haitai Haihe Biomedical Industry Fund and Tianjin Kechuang Angel Investment Co., Ltd. [1] - The company was established in August 2023 and is one of the major technology transfer enterprises of Nankai University, focusing on the functional application research of human milk oligosaccharides (HMOs) [1]. - The founder of the company is Professor Liu Bin from Nankai University, who established the first domestic biosynthesis technology for human milk oligosaccharides in 2016, achieving a breakthrough from "0 to 1" [1]. Group 2 - The company has obtained invention patents for various industrial strains including 2'-FL, 3-FL, 3'-SL, 6'-SL, LNT, LNnT, DFL, and LNFP I, and plans to apply for more than ten additional invention patents [1]. - The HMOs produced by the company have completed small-scale, pilot, and large-scale production, with a product purity of 98.98%, significantly exceeding domestic and international quality standards [1]. - The registered capital of the company is 9.3563 million, with major shareholders including FENG. LU (38.01%), Wang Shuo (16.16%), and Tianjin Nankai University Asset Management Co., Ltd. (10.69%) [2].